Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Appointed director Quarterly results Acq. announced
|
ANI PHARMACEUTICALS INC (ANIP)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
07/21/2011 |
BW
| BioSante Pharmaceuticals Signs Melanoma Vaccine License |
06/07/2011 |
BW
| BioSante Pharmaceuticals, Inc. To Present at Jefferies Global Healthcare Conference |
05/18/2011 |
BW
| BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences |
05/10/2011 |
BW
| BioSante Pharmaceuticals Reports First Quarter Financial Results and Recent Developments |
04/27/2011 |
BW
| BioSante Pharmaceuticals, Inc. To Present at the Deutsche Bank Annual Health Care Conference |
04/18/2011 |
BW
| BioSante Pharmaceuticals Announces Pancreatic and Prostate Cancer Vaccine License |
04/13/2011 |
BW
| BioSante Pharmaceuticals Announces Teva New Drug Application for Bio-T-Gel™ |
04/11/2011 |
BW
| BioSante Pharmaceuticals, Inc. To Present at Future Leaders in the Biotech Industry Conference |
03/30/2011 |
BW
| BioSante Pharmaceuticals Completes Enrollment in Both Pivotal LibiGel® Phase III Efficacy Trials |
03/16/2011 |
BW
| BioSante Pharmaceuticals Reports Financial Results for 2010 and Clinical Development and Business Highlights |
03/09/2011 |
BW
| BioSante Pharmaceuticals Closes $25.1 Million Registered Direct Offering |
03/04/2011 |
BW
| BioSante Pharmaceuticals to Raise $25.1 Million in Registered Direct Offering |
03/03/2011 |
BW
| BioSante's Pancreas Cancer Vaccine Shows Survival Increase in Newly Published Study |
02/24/2011 |
BW
| BioSante Pharmaceuticals Completes Enrollment in LibiGel® Phase III Efficacy Trial |
02/22/2011 |
BW
| BioSante Pharmaceuticals, Inc. to Present at Citi Global Health Care Conference |
02/15/2011 |
BW
| BioSante Presents Data Showing Female Sexual Dysfunction is a Significant Unmet Medical Need |
02/14/2011 |
BW
| BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program |
02/14/2011 |
BW
| BioSante Pharmaceuticals, Inc. To Present LibiGel® Safety Study Update at BIO CEO & Investor Conference |
02/12/2011 |
BW
| BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program |
11/17/2010 |
BW
| BioSante Pharmaceuticals Sells Oncolytic Virus Technology to Cold Genesys, Inc. |
11/12/2010 |
BW
| BioSante Pharmaceuticals Reports Third Quarter 2010 Financial Results |
10/26/2010 |
BW
| BioSante Pharmaceuticals, Inc. To Present at Two Upcoming Investor Conferences |
10/25/2010 |
BW
| BioSante Pharmaceuticals Reports Positive LibiGel® Data Monitoring Committee Recommendation |
10/18/2010 |
BW
| BioSante Pharmaceuticals Reaches Key LibiGel® Safety Study Enrollment Target |
10/14/2010 |
BW
| BioSante Pharmaceuticals, Inc. To Present at Cancer Immunotherapy Conference |
10/11/2010 |
BW
| BioSante Pharmaceuticals, Inc. Presents LibiGel® Clinical Study Update at North American Menopause Society Meeting |
10/04/2010 |
BW
| BioSante Pharmaceuticals, Inc. To Present LibiGel® Clinical Trial Update at North American Menopause Society Meeting |
09/30/2010 |
BW
| BioSante Pharmaceuticals to Present at the Bio Investor Forum |
09/22/2010 |
BW
| BioSante Pharmaceuticals, Inc. To Present at the JMP Healthcare Conference |
08/12/2010 |
BW
| BioSante Pharmaceuticals Reports Second Quarter 2010 Financial Results |
07/13/2010 |
BW
| BioSante Pharmaceuticals Announces Initiation of LibiGel® Study to Evaluate its Effect on Cognitive Function in Women |
06/30/2010 |
BW
| BioSante Pharmaceuticals Announces Positive Clinical Results in Pill-Plus™ Oral Contraceptive Study |
06/23/2010 |
BW
| BioSante Pharmaceuticals Closes $15 Million Registered Direct Offering to Fund LibiGel® for Female Sexual Dysfunction |
06/21/2010 |
BW
| BioSante Pharmaceuticals to Raise $15 Million in Registered Direct Offering |
|
|
|